WO2017209553A3 - Procédé de criblage d'anticorps à l'aide de cellules dérivées de patients - Google Patents

Procédé de criblage d'anticorps à l'aide de cellules dérivées de patients Download PDF

Info

Publication number
WO2017209553A3
WO2017209553A3 PCT/KR2017/005766 KR2017005766W WO2017209553A3 WO 2017209553 A3 WO2017209553 A3 WO 2017209553A3 KR 2017005766 W KR2017005766 W KR 2017005766W WO 2017209553 A3 WO2017209553 A3 WO 2017209553A3
Authority
WO
WIPO (PCT)
Prior art keywords
patient
derived cells
screening antibody
screening
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2017/005766
Other languages
English (en)
Korean (ko)
Other versions
WO2017209553A2 (fr
Inventor
남도현
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Samsung Life Public Welfare Foundation
Original Assignee
Samsung Life Public Welfare Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US16/306,566 priority Critical patent/US11199536B2/en
Priority to EP17807046.2A priority patent/EP3480598A4/fr
Priority to CN201780041974.6A priority patent/CN109416364B/zh
Priority to JP2018562986A priority patent/JP6895460B2/ja
Priority to AU2017273169A priority patent/AU2017273169B2/en
Priority to CA3026236A priority patent/CA3026236C/fr
Application filed by Samsung Life Public Welfare Foundation filed Critical Samsung Life Public Welfare Foundation
Priority to SG11201810779PA priority patent/SG11201810779PA/en
Priority claimed from KR1020170069140A external-priority patent/KR101993892B1/ko
Publication of WO2017209553A2 publication Critical patent/WO2017209553A2/fr
Publication of WO2017209553A3 publication Critical patent/WO2017209553A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Landscapes

  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne un procédé de criblage d'un anticorps ou d'un fragment de liaison à l'antigène de celui-ci à l'aide de cellules dérivées de patients et, plus particulièrement, un procédé de criblage d'un anticorps se liant spécifiquement à un antigène ou à un fragment de liaison à l'antigène de celui-ci à l'aide de cellules dérivées d'un patient contenant l'antigène.
PCT/KR2017/005766 2016-06-03 2017-06-02 Procédé de criblage d'anticorps à l'aide de cellules dérivées de patients Ceased WO2017209553A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP17807046.2A EP3480598A4 (fr) 2016-06-03 2017-06-02 Procédé de criblage d'anticorps à l'aide de cellules dérivées de patients
CN201780041974.6A CN109416364B (zh) 2016-06-03 2017-06-02 使用患者来源的肿瘤球体筛选抗体的方法
JP2018562986A JP6895460B2 (ja) 2016-06-03 2017-06-02 患者由来腫瘍スフェロイドを用いた抗体スクリーニング方法
AU2017273169A AU2017273169B2 (en) 2016-06-03 2017-06-02 Method for screening antibody using patient-derived tumor spheroids
CA3026236A CA3026236C (fr) 2016-06-03 2017-06-02 Procede de criblage d'anticorps a l'aide de cellules derivees de patients
US16/306,566 US11199536B2 (en) 2016-06-03 2017-06-02 Method for screening antibody using patient-derived tumor spheroids
SG11201810779PA SG11201810779PA (en) 2016-06-03 2017-06-02 Method for screening antibody using patient-derived tumor spheroids

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2016-0069355 2016-06-03
KR20160069355 2016-06-03
KR10-2017-0069140 2017-06-02
KR1020170069140A KR101993892B1 (ko) 2016-06-03 2017-06-02 환자 유래 세포를 이용한 항체 스크리닝 방법

Publications (2)

Publication Number Publication Date
WO2017209553A2 WO2017209553A2 (fr) 2017-12-07
WO2017209553A3 true WO2017209553A3 (fr) 2018-01-18

Family

ID=60477675

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2017/005766 Ceased WO2017209553A2 (fr) 2016-06-03 2017-06-02 Procédé de criblage d'anticorps à l'aide de cellules dérivées de patients

Country Status (1)

Country Link
WO (1) WO2017209553A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210082207A (ko) 2018-10-23 2021-07-02 리제너론 파아마슈티컬스, 인크. 항-npr1 항체 및 이의 용도
US12325752B2 (en) 2020-12-18 2025-06-10 Regeneron Pharmaceuticals, Inc. Immunoglobulin proteins that bind to NPR1 agonists
JP2024542823A (ja) 2021-12-06 2024-11-15 リジェネロン・ファーマシューティカルズ・インコーポレイテッド アンタゴニスト抗ｎｐｒ１抗体およびその使用方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020199212A1 (en) * 2001-05-10 2002-12-26 Saburo Sone Non-human animal exhibiting bone metastasis of tumor cells and method of screening for bone metastasis inhibitors
KR101096359B1 (ko) * 2005-11-08 2011-12-20 제넨테크, 인크. 뉴로필린 길항제
KR20120048563A (ko) * 2009-06-22 2012-05-15 번햄 인스티튜트 포 메디칼 리서치 Ｃ?말단 요소를 가진 펩타이드 및 단백질의 사용방법 및 그 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
EP0281604B1 (fr) 1986-09-02 1993-03-31 Enzon Labs Inc. Molecules de liaison de chaines de polypeptide simples
ATE114723T1 (de) 1987-03-02 1994-12-15 Enzon Lab Inc Organismus als träger für ''single chain antibody domain (scad)''.
EP0305500B1 (fr) 1987-03-20 1994-11-09 Creative Biomolecules, Inc. Procede de purification de polypeptides recombinants
WO1988007086A1 (fr) 1987-03-20 1988-09-22 Creative Biomolecules, Inc. Sequences d'amorce pour la production de proteines recombinantes
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
WO2011143408A1 (fr) 2010-05-13 2011-11-17 Genentech, Inc. Utilisation d'antagonistes de la neuropiline 1 pour le traitement du cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020199212A1 (en) * 2001-05-10 2002-12-26 Saburo Sone Non-human animal exhibiting bone metastasis of tumor cells and method of screening for bone metastasis inhibitors
KR101096359B1 (ko) * 2005-11-08 2011-12-20 제넨테크, 인크. 뉴로필린 길항제
KR20120048563A (ko) * 2009-06-22 2012-05-15 번햄 인스티튜트 포 메디칼 리서치 Ｃ?말단 요소를 가진 펩타이드 및 단백질의 사용방법 및 그 조성물

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
WILLIAMS ET AL.: "Identification of an Antibody Fragment Specific for Androgen-dependent Prostate Cancer Cells", BMC BIOTECHNOLOGY, vol. 4, 3 September 2014 (2014-09-03), pages 1 - 11, XP021195833 *
WILLIAMS ET AL.: "In Vitro Selection of Cancer Cell -specific Molecular Recognition Elements from Amino Acid Libraries", JOURNAL OF IMMUNOLOGY RESEARCH, vol. 2015, 7 September 2015 (2015-09-07), pages 1 - 12, XP055556675 *

Also Published As

Publication number Publication date
WO2017209553A2 (fr) 2017-12-07

Similar Documents

Publication Publication Date Title
IL277072A (en) Anti-claudin antibodies 18.2
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
WO2018109170A3 (fr) Anticorps il-11ra
PH12019502087A1 (en) Anti-par2 antibodies and uses thereof
WO2017147542A3 (fr) Conjugaison optimisée d'anticorps spécifique d'un site de transglutaminase
WO2018109174A3 (fr) Anticorps anti-il-11
WO2017106684A3 (fr) Anticorps se liant spécifiquement à hla-dr et leurs utilisations
WO2016077381A8 (fr) Anticorps anti-interleukine 33 et leurs utilisations
MY195993A (en) Antibodies and Antibody Fragments for Site-Specific Conjugation
EP3176181A4 (fr) Anticorps monoclonal anti-ctla4 ou fragment de celui-ci se liant à l'antigène, composition médicinale et son utilisation
WO2015091853A3 (fr) Anticorps
WO2015127136A3 (fr) Anticorps monoclonaux anti-ebola
WO2015187018A3 (fr) Moyens et procédés pour déterminer une reconnaissance de lymphocytes t
WO2018071910A3 (fr) Anticorps anti-il1-rap
MY189618A (en) Antibody specifically binding to pd-1 and functional fragment thereof
WO2016205427A3 (fr) Protéines de liaison contre vegf, pdgf et/ou leurs récepteurs
WO2015075269A9 (fr) Anticorps dirigés contre ccr9 et leurs applications
WO2015200522A3 (fr) Anticorps monoclonaux dirigés contre des glycoprotéines d'enveloppe de multiples espèces de filovirus
MY185578A (en) Antibody specifically binding to il-17a and functional fragment thereof
WO2015006337A3 (fr) Compositions et procédés permettant d'augmenter la demi-vie d'une protéine dans un sérum
IL291082A (en) Anti-vsig4 antibody or antigen-binding fragment and uses thereof
WO2017200981A8 (fr) Anticorps anti-facteur ix padua
WO2018138681A9 (fr) Anticorps spécifiques de l'hémagglutinine et leurs utilisations
WO2017209553A3 (fr) Procédé de criblage d'anticorps à l'aide de cellules dérivées de patients
WO2019133902A3 (fr) Anticorps et dosages pour ccl14

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17807046

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2018562986

Country of ref document: JP

Kind code of ref document: A

Ref document number: 3026236

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2017807046

Country of ref document: EP

Effective date: 20190103

ENP Entry into the national phase

Ref document number: 2017273169

Country of ref document: AU

Date of ref document: 20170602

Kind code of ref document: A